Geode Capital Management’s SAB Biotherapeutics SABS Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $148K | Buy |
84,772
+87
| +0.1% | +$152 | ﹤0.01% | 3963 |
|
|
2025
Q1 | $114K | Buy |
84,685
+4,451
| +6% | +$6.01K | ﹤0.01% | 3999 |
|
|
2024
Q4 | $307K | Buy |
80,234
+12,692
| +19% | +$48.5K | ﹤0.01% | 3752 |
|
|
2024
Q3 | $182K | Buy |
67,542
+8,127
| +14% | +$21.9K | ﹤0.01% | 3930 |
|
|
2024
Q2 | $184K | Sell |
59,415
-4,051
| -6% | -$12.6K | ﹤0.01% | 3945 |
|
|
2024
Q1 | $288K | Buy |
63,466
+27,830
| +78% | +$126K | ﹤0.01% | 3811 |
|
|
2023
Q4 | $245K | Hold |
35,636
| – | – | ﹤0.01% | 3865 |
|
|
2023
Q3 | $225K | Buy |
35,636
+5,583
| +19% | +$35.2K | ﹤0.01% | 3935 |
|
|
2023
Q2 | $249K | Hold |
30,053
| – | – | ﹤0.01% | 3944 |
|
|
2023
Q1 | $132K | Hold |
30,053
| – | – | ﹤0.01% | 4236 |
|
|
2022
Q4 | $177K | Sell |
30,053
-1,613
| -5% | -$9.5K | ﹤0.01% | 4162 |
|
|
2022
Q3 | $221K | Hold |
31,666
| – | – | ﹤0.01% | 4153 |
|
|
2022
Q2 | $459K | Buy |
31,666
+1,555
| +5% | +$22.5K | ﹤0.01% | 3821 |
|
|
2022
Q1 | $1.13M | Buy |
30,111
+770
| +3% | +$28.9K | ﹤0.01% | 3558 |
|
|
2021
Q4 | $2.29M | Buy |
+29,341
| New | +$2.29M | ﹤0.01% | 3300 |
|